Evidence map›Paper›PMID 40053177›Full record

Observational studyAnnals of nuclear medicine2025

Ga-68 Pentixafor PET/CT in multiple myeloma and its correlation with clinical parameters: institutional pilot study.

Dinesh Kumar Gauthaman, Indirani Muthukrishnan, K Ashish Acharya, Shelley Simon

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dinesh Kumar GauthamanDepartment of Nuclear Medicine, Apollo Hospitals, Greams Lane, 21, Greams Road, Thousand Lights, Chennai, Tamil Nadu, 600006, India.
Indirani MuthukrishnanDepartment of Nuclear Medicine, Apollo Hospitals, Greams Lane, 21, Greams Road, Thousand Lights, Chennai, Tamil Nadu, 600006, India.
K Ashish AcharyaDepartment of Nuclear Medicine, Apollo Hospitals, Greams Lane, 21, Greams Road, Thousand Lights, Chennai, Tamil Nadu, 600006, India.
Shelley SimonDepartment of Nuclear Medicine, Apollo Hospitals, Greams Lane, 21, Greams Road, Thousand Lights, Chennai, Tamil Nadu, 600006, India. shelleysimon@rediffmail.com.ORCID http://orcid.org/0009-0006-6612-8703

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study evaluates the role of Ga-68 Pentixafor PET/CT in staging and follow-up of multiple myeloma (MM) and its correlation with clinical parameters.

methodsThirteen participants (9 males, 4 females; median age: 65 years) with MM were recruited in this prospective observational study. Six participants were included for staging evaluation, seven were included for follow-up evaluation, and underwent Ga-68 Pentixafor PET/CT. Focal PET-positive bone marrow lesions or diffuse bone marrow uptake (uptake more than liver) was considered a positive scan. The quantitative variables like SUVmax, SUVmean, total bone marrow volume and uptake (TBMV & TBMU) and tumor to background ratio (TBRmax) were obtained. Durie Salmon Plus Staging (DSPS) was used for MM staging by PET/CT and was compared with the International Staging System (ISS). Statistical comparison was performed between PET/CT quantitative variables and laboratory parameters.

resultsTwelve participants (12/13) had positive Ga-68 Pentixafor PET/CT, among which one was diagnosed to have anemia of chronic disease. One participant (1/13) who was clinically negative on follow-up had negative Ga-68 Pentixafor PET/CT. The sensitivity, specificity, PPV and NPV of Ga-68 Pentixafor PET/CT in MM (95% CI) were observed to be 100%, 50%, 91.6% and 100%, respectively. The correlation between DSPS and ISS in the patients who came for staging scans was found to be statistically significant (p-value 0.02). In quantitative analysis, either of the quantitative variables in Ga-68 Pentixafor PET/CT was positively correlated with clinical parameters related to tumor burden like CRAB score, serum protein electrophoresis M-protein, beta 2 microglobulin, LDH, percentage of plasma cells infiltrates in bone marrow aspiration, ISS, serum free light chain and negatively correlated with hemoglobin, albumin (p < 0.5).

conclusionGa-68 Pentixafor PET/CT is a promising tracer and the only available non-invasive tool to assess the whole-body disease burden of CXCR4 receptors in staging and follow-up of MM. In addition, it has a vital role in the development of CXCR4-targeted theranostics. Dual tracer imaging using F-18 FDG and Ga-68 Pentixafor PET/CT may help in evaluating tumor heterogeneity in MM and add prognostic value at diagnosis and follow-up.

Indexed as

IronMultiple MyelomaPositron Emission Tomography Computed TomographyAgedAged, 80 and overCoordination ComplexesFemaleGallium RadioisotopesHumansMaleMiddle AgedNeoplasm StagingPeptides, CyclicPilot ProjectsProspective Studies68Ga-pentixaforCoordination ComplexesGallium RadioisotopesIronPeptides, CyclicCXCR4 PETMultiple myelomaPentixafor PETQuantitative parameters

Identifiers

PMID40053177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.